![](https://d3ilqtpdwi981i.cloudfront.net/hcJTd-Bq64BGSGOU4qrS85olrtQ=/0x54:371x534/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/28/ff/1f/28ff1ff6-919f-41e5-b47f-e4f5b57547c5/BHSF%20Pineapple%20Logo%20%28Imported%20Works%29.png)
Article
PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5
Hematological Oncology
(2021)
Disciplines
Publication Date
June 17, 2021
DOI
10.1002/HON.163_2880
Citation Information
C. Carlo-Stella, Y. Linhares, M. D. Gandhi, M. Chung, et al.. "PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5" Hematological Oncology Vol. 39 (2021) Available at: http://works.bepress.com/yuliya-linhares/36/